Tris(2-ethylhexyl) phosphate (TEHP) is a colorless, odorless liquid used as a plasticizer. It is synthesized by reacting phosphorus oxychloride with 2-ethylhexanol. TEHP is used in a variety of applications, including PVC plasticizers, hydraulic fluids, and fire retardants. TEHP is a potential endocrine disruptor and has been shown to cause developmental and reproductive problems in animals. It is also a persistent organic pollutant and can bioaccumulate in the food chain. TEHP is studied due to its potential environmental and health effects. '
ID Source | ID |
---|---|
PubMed CID | 6537 |
CHEMBL ID | 1562290 |
CHEBI ID | 181994 |
SCHEMBL ID | 35485 |
MeSH ID | M0141144 |
Synonym |
---|
tehp |
CHEBI:181994 |
AKOS015843194 |
1-hexanol, 2-ethyl-, phosphate |
tris(ethylhexyl) phosphate |
tris(2-ethylhexyl) phosphate |
disflamoll tof |
phosphoric acid, tris(2-ethylhexyl) ester |
78-42-2 |
TOF , |
tri(2-ethylhexyl) phosphate |
wln: 4y2&1opo&o1y4&2&o1y4&2 |
tri(ethylhexyl) phosphate |
nsc-407921 |
nci-c54751 |
flexol tof |
nsc407921 |
1-hexanol, phosphate |
flexol plasticizer tof |
phosphoric acid, tris(ethylhexyl) ester |
2-ethyl-1-hexanol phosphate |
tris(2-ethylhexyl)phosphate |
NCGC00091821-01 |
inchi=1/c24h51o4p/c1-7-13-16-22(10-4)19-26-29(25,27-20-23(11-5)17-14-8-2)28-21-24(12-6)18-15-9-3/h22-24h,7-21h2,1-6h |
tri(2-ethylhexyl)phosphate |
ai3-07852 |
hsdb 2562 |
einecs 201-116-6 |
nsc 407921 |
triethylhexyl phosphate |
kronitex tof |
tris-(2-ethylhexyl)fosfat [czech] |
phosphoric acid, tris(2-ethylhexyl)ester |
tris-2(2-ethylhexyl)fosfat [czech] |
ccris 615 |
tris(2-ethylhexy)phosphate |
brn 1715839 |
2-ethylhexanol, phosphate triester |
tris(2-ethylhexyl) phosphate, 97% |
smr001370923 |
MLS002415769 |
phosphoric acid tris(2-ethylhexyl) ester |
phosphoric acid trioctyl ester |
P1022 |
NCGC00091821-03 |
NCGC00091821-02 |
HMS3039O17 |
NCGC00254160-01 |
NCGC00258921-01 |
tox21_201369 |
tox21_300321 |
dtxcid801414 |
dtxsid0021414 , |
cas-78-42-2 |
tris-(2-ethylhexyl)fosfat |
unii-bqc0bkb72s |
tris-2(2-ethylhexyl)fosfat |
ec 201-116-6 |
bqc0bkb72s , |
tris(2-ethylhexyl) phosphate [hsdb] |
SCHEMBL35485 |
CHEMBL1562290 |
2-ethylhexanol phosphate (3:1) |
amgard tof |
GTVWRXDRKAHEAD-UHFFFAOYSA-N |
tris(2-ethylhexyl) phosphate, selectophore(tm), >=99.0% |
mfcd00009491 |
tris(2-ethylhexl)phosphate |
Q2454094 |
A865029 |
CS-W009670 |
trioctyl phosphate (top) |
'trioctyl' phosphate |
Excerpt | Relevance | Reference |
---|---|---|
" Measures to prevent 2E1H emission and dose-response relationships in sensitive individuals should be studied further." | ( [Indoor air pollution due to 2-ethyl-1-hexanol airborne concentrations, emission sources and subjective symptoms in classroom users]. Ishihara, S; Kamijima, M; Nakajima, T; Ohno, H; Sakai, K; Shibata, E; Takeuchi, Y; Yamada, T, 2005) | 0.33 |
Class | Description |
---|---|
trialkyl phosphate | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ATAD5 protein, partial | Homo sapiens (human) | Potency | 23.0999 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 23.7246 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
AR protein | Homo sapiens (human) | Potency | 7.2568 | 0.0002 | 21.2231 | 8,912.5098 | AID743036; AID743040; AID743053 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 61.7528 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 30.9497 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 4.8558 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 3.5508 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743080 |
67.9K protein | Vaccinia virus | Potency | 3.2465 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
IDH1 | Homo sapiens (human) | Potency | 58.0479 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 2.4800 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 4.8966 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 6.3096 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 1.1595 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 2.7306 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 7 (50.00) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.06) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |